A head-to-head registration study of AVR-RD-01 compared to Fabrazyme for the treatment of Fabry disease
Latest Information Update: 24 Jul 2024
Price :
$35 *
At a glance
- Drugs AVR RD 01 (Primary) ; Agalsidase beta
- Indications Fabry's disease
- Focus Registrational; Therapeutic Use
- Sponsors AVROBIO; Tectonic Therapeutic
- 20 Jun 2024 According to a Tectonic Therapeutic media release, AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic.
- 06 May 2021 New trial record
- 03 May 2021 According to a AVROBIO media release, the company intends to seek scientific advice from the European Medicines Agency on this planned registration trial.